

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 64633

**Title:** Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions

**Reviewer's code:** 04559712

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-03-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-04-13 02:24

**Reviewer performed review:** 2021-04-26 09:51

**Review time:** 13 Days and 7 Hours

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Re-review</b>                | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No   |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |

## **SPECIFIC COMMENTS TO AUTHORS**

The authors demonstrates a very-well and comprehensive review on RFA and immunotherapy in advanced HCCs. Here are some comments:

1. Page 4: "In addition, patients with recurrent HCCs >2 cm beyond Milan criteria after RFA as first-line therapy had greater risk of recurrence." The statement is confusing. The study (reference 14) showed "Tumor size >2 cm and alpha-fetoprotein levels at the time of ablation were predictors of post-RFA recurrence outside Milan criteria." , not "recurrent HCCs >2cm". Please revise it.
2. Page 5: "Shin et al[12] concluded that HR was better than MWA or RFA plus TACE in terms of OS and recurrence free survival (RFS) for HCCs within Milan criteria." HR should be replaced with "SR".
3. Page 5: "currenting being evaluated in some ongoing clinical studies". "currenting" is misspelled.
4. Page 6: "advanced-stage HCC in a recent systematic review and pooled analysis of 2,402 patients suffering from HCC". Please delete "suffering from HCC", because "advanced-stage HCC" is already mentioned.
5. Page 11: "The results showed that more intrahepatic and extrahepatic recurrence was identified in the control group (7.1% vs. 40%). " The statement is confusing: which number is treatment group? I did not found this data according to the reference. Please revise it.
6. Page 11: "The results showed that the patients in the TACE + MWA + CIK group have higher overall response rate (74.42% (32/43) vs. 77.19% (44/57), P = 0.243) and disease control rate (87.72% vs. 79.07%, P = 0.748)." Which number represents treatment group? The P-values are not significant, which should be mentioned.
7. Table 2: Reference 71 and 83 did not match the authors.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 64633

**Title:** Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions

**Reviewer's code:** 04559712

**Position:** Editorial Board

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Taiwan

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-03-01

**Reviewer chosen by:** Han Zhang (Online Science Editor)

**Reviewer accepted review:** 2021-07-18 23:48

**Reviewer performed review:** 2021-08-01 03:14

**Review time:** 13 Days and 3 Hours

|                                 |   |
|---------------------------------|---|
| <b>Scientific quality</b>       | <input checked="" type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good<br><input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish            |
| <b>Language quality</b>         | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing<br><input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| <b>Conclusion</b>               | <input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority)<br><input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection             |
| <b>Peer-reviewer statements</b> | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous<br>Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No   |

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

The author revised the manuscript appropriately. I have no other comments.